5eqo: Difference between revisions
No edit summary |
No edit summary |
||
(2 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
The | ==Human Angiogenin in complex with sulphate anions at an acidic solution== | ||
<StructureSection load='5eqo' size='340' side='right'caption='[[5eqo]], [[Resolution|resolution]] 2.40Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[5eqo]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5EQO OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5EQO FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.4Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5eqo FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5eqo OCA], [https://pdbe.org/5eqo PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5eqo RCSB], [https://www.ebi.ac.uk/pdbsum/5eqo PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5eqo ProSAT]</span></td></tr> | |||
</table> | |||
== Disease == | |||
[https://www.uniprot.org/uniprot/ANGI_HUMAN ANGI_HUMAN] Defects in ANG are the cause of susceptibility to amyotrophic lateral sclerosis type 9 (ALS9) [MIM:[https://omim.org/entry/611895 611895]. ALS is a degenerative disorder of motor neurons in the cortex, brain stem and spinal cord. ALS is characterized by muscular weakness and atrophy.<ref>PMID:17886298</ref> <ref>PMID:15557516</ref> <ref>PMID:16501576</ref> <ref>PMID:17900154</ref> <ref>PMID:18087731</ref> <ref>PMID:17703939</ref> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/ANGI_HUMAN ANGI_HUMAN] May function as a tRNA-specific ribonuclease that abolishes protein synthesis by specifically hydrolyzing cellular tRNAs. Binds to actin on the surface of endothelial cells; once bound, angiogenin is endocytosed and translocated to the nucleus. Angiogenin induces vascularization of normal and malignant tissues. Angiogenic activity is regulated by interaction with RNH1 in vivo.<ref>PMID:1400510</ref> <ref>PMID:19354288</ref> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
In this study, we investigate the inhibition of human angiogenin by ammonium sulfate. The inhibitory potency of ammonium sulfate for human angiogenin (IC50 = 123.5 +/- 14.9 mm) is comparable to that previously reported for RNase A (119.0 +/- 6.5 mm) and RNase 2 (95.7 +/- 9.3 mm). However, analysis of two X-ray crystal structures of human angiogenin in complex with sulfate anions (in acidic and basic pH environments, respectively) indicates an entirely distinct mechanism of inhibition. While ammonium sulfate inhibits the ribonucleolytic activity of RNase A and RNase 2 by binding to the active site of these enzymes, sulfate anions bind only to peripheral substrate anion-binding subsites of human angiogenin, and not to the active site. | |||
The ammonium sulfate inhibition of human angiogenin.,Chatzileontiadou DS, Tsirkone VG, Dossi K, Kassouni AG, Liggri PG, Kantsadi AL, Stravodimos GA, Balatsos NA, Skamnaki VT, Leonidas DD FEBS Lett. 2016 Sep;590(17):3005-18. doi: 10.1002/1873-3468.12335. Epub 2016 Aug , 12. PMID:27483019<ref>PMID:27483019</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: Chatzileontiadou | <div class="pdbe-citations 5eqo" style="background-color:#fffaf0;"></div> | ||
[[Category: Leonidas | |||
==See Also== | |||
*[[Ribonuclease 3D structures|Ribonuclease 3D structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | |||
[[Category: Chatzileontiadou DSM]] | |||
[[Category: Leonidas DD]] |
Latest revision as of 11:17, 12 July 2023
Human Angiogenin in complex with sulphate anions at an acidic solutionHuman Angiogenin in complex with sulphate anions at an acidic solution
Structural highlights
DiseaseANGI_HUMAN Defects in ANG are the cause of susceptibility to amyotrophic lateral sclerosis type 9 (ALS9) [MIM:611895. ALS is a degenerative disorder of motor neurons in the cortex, brain stem and spinal cord. ALS is characterized by muscular weakness and atrophy.[1] [2] [3] [4] [5] [6] FunctionANGI_HUMAN May function as a tRNA-specific ribonuclease that abolishes protein synthesis by specifically hydrolyzing cellular tRNAs. Binds to actin on the surface of endothelial cells; once bound, angiogenin is endocytosed and translocated to the nucleus. Angiogenin induces vascularization of normal and malignant tissues. Angiogenic activity is regulated by interaction with RNH1 in vivo.[7] [8] Publication Abstract from PubMedIn this study, we investigate the inhibition of human angiogenin by ammonium sulfate. The inhibitory potency of ammonium sulfate for human angiogenin (IC50 = 123.5 +/- 14.9 mm) is comparable to that previously reported for RNase A (119.0 +/- 6.5 mm) and RNase 2 (95.7 +/- 9.3 mm). However, analysis of two X-ray crystal structures of human angiogenin in complex with sulfate anions (in acidic and basic pH environments, respectively) indicates an entirely distinct mechanism of inhibition. While ammonium sulfate inhibits the ribonucleolytic activity of RNase A and RNase 2 by binding to the active site of these enzymes, sulfate anions bind only to peripheral substrate anion-binding subsites of human angiogenin, and not to the active site. The ammonium sulfate inhibition of human angiogenin.,Chatzileontiadou DS, Tsirkone VG, Dossi K, Kassouni AG, Liggri PG, Kantsadi AL, Stravodimos GA, Balatsos NA, Skamnaki VT, Leonidas DD FEBS Lett. 2016 Sep;590(17):3005-18. doi: 10.1002/1873-3468.12335. Epub 2016 Aug , 12. PMID:27483019[9] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|